Samuel Multack, DO
Ophthalmology · Olympia Fields, ILNPI 1619135233
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $21,176 of the $33,658 with a category attached, or 62.9%. Alcon accounts for 82.7% of it on its own, with 35 other manufacturers making up the rest. Reporting peaked in 2021 at $9,776 and has fallen 83.7% since, to $1,590 in 2025. Among ophthalmology clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 402 payments — averaging $83.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$28K
- AbbVie$2K
- Bausch & Lomb Americas Inc.$524
- Aerie Pharmaceuticals, Inc.$322
- Bausch & Lomb, A Division Of Bausch Health US, LLC$317
- Rxsight Inc$269
- plus $2K from 30 others
Across 49 payments — averaging $4871.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$239K
What the payments were for
- Consulting fees$21,17663%
- Speaking & faculty fees$7002%
- Travel & lodging$2,3677%
- Food & beverage$9,35528%
- Education$80%
- Gifts$520%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARGOS$11,264
- Capella Aberrometer$2,625
- Centurion$897
- RESTASIS$750
- NGENUITY$584
- DAILIES$404
- Rhopressa$124
- Rocklatan$124
- LUMIGAN$124
- Clareon$122
- RXSIGHT INJECTOR HANDPIECE$100
- RXSIGHT CONTACT LENS$100
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$100
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$100
- RXSIGHT INJECTOR CARTRIDGE$100
How this compares
$33,658 in reported general payments places this provider in the 90th percentile of 773 ophthalmology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 49 | $62,326 |
| LumiganBimatoprost | 67 | $47,665 |
| MieboPerfluorohexyloctane/Pf | 28 | $36,041 |
| RocklatanNetarsudil Mesylat/Latanoprost | 27 | $28,023 |
| RhopressaNetarsudil Mesylate | 29 | $25,580 |
| XiidraLifitegrast | 12 | $25,025 |
| ProlensaBromfenac Sodium | 67 | $23,896 |
| Lotemax SmLoteprednol Etabonate | 77 | $19,770 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 38 | $19,435 |
| BesivanceBesifloxacin Hcl | 65 | $14,735 |
| Cyclosporine | 19 | $13,513 |
| CombiganBrimonidine Tartrate/Timolol | 16 | $11,495 |
| Latanoprost | 738 | $11,162 |
| VyzultaLatanoprostene Bunod | 17 | $10,177 |
| Brimonidine Tartrate | 323 | $5,169 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $2,064 | $121,486132 claims |
| Bausch & Lomb Americas Inc.Miebo, Xiidra, Vyzulta | $524 | $71,24457 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm, Besivance, Loteprednol Etabonate | $317 | $62,517225 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $322 | $53,60356 claims |
| AlconSimbrinza | $27,824 | $19,43538 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 773 ophthalmology providers in Illinois.
Other ophthalmology in Olympia Fields
- Sharon BurkeOlympia Fields$31K
- Seenu HariprasadChicago$2.3M
- Lisa NijmSpringfield$1.7M
- Kathleen MornoNorth Riverside$1.2M
- Veeral ShethOak Forest$716K
- James KatzDes Plaines$642K
- Mitchell JacksonLake Villa$584K
- David LubeckHomewood$575K
- Parag MajmudarHighland Park$451K
- Daniel OwensLombard$343K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.